THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today released top-line findings from its six month study of Proellex™ in the treatment of endometriosis. This study, conducted in Europe, enrolled 39 premenopausal women and has completed six months of dosing. The study included three dose levels of Proellex™ as well as a positive control arm. The positive control was Lucrin®, a GnRH agonist also known as Lupron® or leuprolide acetate, commonly used for the treatment of endometriosis. Proellex was administered in a double blinded fashion as a daily oral dose of either 12.5mg, 25mg, or 50mg capsules. Data from this study demonstrate that treatment with the 50mg Proellex dose reduces both the duration and intensity of pain more effectively than 12.5mg or 25mg and is significantly better (p = 0.0012) than Lucrin in reducing the number of days of pain over the course of the study. Pain reduction also occurred more rapidly than with the active control, Lucrin. Biomarkers of bone loss were unchanged on Proellex therapy but increased on Lucrin.
